interleukin inhibitors

R&D

The rise and market race of anti-IL23p19 therapies in IBD: H...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two decades.

News

Novo Nordisk diversifies with $2.1bn deal to buy Corvidia

Novo Nordisk has taken another step towards expanding beyond its heartlands of diabetes and obesity with a deal to buy US biotech Corvidia Therapeutics and its lead drug for ch

Views & Analysis

3 key trends shaping the immunology market

From an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an eventful one in the immunology industry.

The rise and market race of anti-IL23p19 therapies in IBD: H...

Novo Nordisk diversifies with $2.1bn deal to buy Corvidia

3 key trends shaping the immunology market

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

Editor's Picks